Suanfarma Appoints Pere Mañé Godina as New CEO

• Suanfarma announces the appointment of Pere Mañé Godina as its new Chief Executive Officer, bringing over 30 years of pharmaceutical and CDMO leadership experience.

• His leadership will focus on optimizing industrial operations, accelerating global expansion, and fostering innovation and sustainability.

Suanfarma, a global leader in the pharmaceutical industry, has appointed Pere Mañé Godina as its new Chief Executive Officer. With more than 30 years of experience in pharmaceutical operations and contract development and manufacturing (CDMO), Pere’s arrival signals a major step forward in Suanfarma’s journey towards industrial consolidation and sustainable innovation.

Pere Mañé Godina has an impressive track record, having held leadership roles at renowned companies such as Uquifa, Boehringer Ingelheim, and Esteve Química. His most recent role involved spearheading the industrial transformation at Esteve, where he guided the chemical division to become a global benchmark and led the company to win the “CDMO of the Year – Small Molecules” 2025 CDMO Leadership Awards.

As Suanfarma’s new CEO, Pere aims to build on the company’s strong foundation by optimizing industrial operations, integrating advanced technologies, and accelerating international growth. Carlos Alonso, who has served as interim CEO, will continue in his role as Executive Chairman to ensure a smooth leadership transition.

Pere expressed his enthusiasm for the role, stating, “Suanfarma has all the key elements to lead the future of the industry… I’m excited to begin this new chapter and to work together in delivering innovative, efficient, and sustainable solutions to our clients.”